Medtronic has made a strategic investment of up to $80 million in Pi-Cardia, a company specializing in leaflet modification technologies for structural heart disease. This investment supports Medtronic's goal to enhance its structural heart portfolio, particularly for complex transcatheter aortic valve replacement (TAVR) procedures. Pi-Cardia's ShortCut™ device, FDA-cleared for valve-in-valve TAVR, helps prevent coronary obstruction and preserves coronary access. Medtronic plans to become the exclusive global distributor of ShortCut in 2027 and has an option to acquire Pi-Cardia upon meeting certain milestones, potentially paying up to $210 million upfront plus earn-outs. This collaboration aims to improve patient outcomes and expand treatment options in structural heart care.
Medtronic announced a 13.7% increase in revenue to $9.8 billion for Q1 of fiscal year 2027, driven by strong growth across cardiovascular, neuroscience, and medical surgical segments. The company raised its full-year organic revenue growth guidance t...
Despite two major recessions in the past two decades, four healthcare companies—Johnson & Johnson, Abbott Laboratories, Medtronic, and Becton Dickinson—consistently raised their dividends each quarter. Their strong cash flows and inelastic demand for...
The August jobs report is crucial for the Federal Reserve's decision on a potential September rate hike, with strong labor data increasing the odds. Broadcom faces downside risk ahead of earnings due to high AI expectations, while Apple transitions t...
